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   ABSTRACT 
   Background      To develop preliminary classiﬁ  cation criteria 
for the cryoglobulinaemic syndrome or cryoglobulinaemic 
vasculitis (CV).   
  Methods     Study part I developed a questionnaire for CV 
to be included in the formal, second part (study part II). 
Positivity of serum cryoglobulins was deﬁ  ned by experts 
as an essential condition for CV classiﬁ  cation. In study 
part II, a core set of classiﬁ  cation items (questionnaire, 
clinical and laboratory items, as agreed) was tested 
in three groups of patients and controls—that is, 
group A (new patients with the CV), group B (controls 
with serum cryoglobulins but lacking CV) and group C 
(controls without serum cryoglobulins but with features 
which can be observed in CV).   
  Results     In study part I (188 cases, 284 controls), a 
positive response to at least two of three selected 
questions showed a sensitivity of 81.9% and a speciﬁ  city 
of 83.5% for CV. This questionnaire was employed and 
validated in study part II, which included 272 patients 
in group A and 228 controls in group B. The ﬁ  nal 
classiﬁ  cation criteria for CV, by pooling data from group 
A and group B, required the positivity of questionnaire 
plus clinical, questionnaire plus laboratory, or clinical plus 
laboratory items, or all the three, providing a sensitivity 
of 88.5% and a speciﬁ  city of 93.6% for CV. By comparing 
data in group A versus group C (425 controls), the same 
classiﬁ  cation criteria showed a sensitivity 88.5% and a 
speciﬁ  city 97.0% for CV.   
  Conclusion     Classiﬁ  cation criteria for CV were 
developed,  and  now  need  validation.      
  Cryoglobulinaemic syndrome or cryoglobulinaemic 
vasculitis (CV) is a systemic vasculitis associated with 
serum positive cryoglobulins—that is, immune com-
plexes composed of rheumatoid factor (RF) mono-
clonal or polyclonal against polyclonal IgG (type II 
or type III cryoglobulins, respectively) or immuno-
globulins without RF activity (type I), which revers-
ibly precipitate or form a gel at a temperature below 
37°C.  1     2   CV is usually linked to non-  malignant B-cell 
lymphoproliferation,  3   often triggered by chronic 
hepatitis C virus (HCV)   infection.  4     5   
  Classiﬁ   cation criteria developed with an 
accepted methodology are presently lacking for 
CV, while a correct classiﬁ  cation is a key step for 
clinical practice, research and epidemiological 
studies.  6    –    14   Previous criteria were not universal 
and lacked appropriate statistical support.  9    –    12   This 
study was therefore started, involving different 
European experts. It was divided into two parts, 
the ﬁ  rst dedicated to the development of a ques-
tionnaire showing the highest sensitivity and 
speciﬁ  city for CV, which was then included in the 
second part of the study (part II), where the stan-
dard methodology for classiﬁ  cation studies was 
used.  13     14   
  MATERIALS  AND  METHODS 
  The study was proposed by GISC (Italian Study 
Group on Cryoglobulinemia). The experts agreed 
on four key points for the study development:       
▶  Classiﬁ  cation criteria are necessary for all 
the patients with CV, either HCV-related 
or HCV-unrelated. 
▶        The presence of serum cryoglobulins (either 
type I, II, III, or not typiﬁ  able) is an essential 
condition for the classiﬁ  cation of CV. 
▶        The study protocol should be divided 
into two parts: part I, to develop a dedi-
cated questionnaire for patients with CV, 
and part II—that is, the formal study, to 
develop the classiﬁ  cation criteria, using a 
standard methodology and including the 
questions selected in study part I.  13   
▶        The core set of items for the classiﬁ  cation of 
CV should include the dedicated question-
naire plus the presence of easily accessible 
clinical manifestations and laboratory tests. 
For this reason, histopathology, ﬂ  ow cytom-
etry studies and novel laboratory biomarkers 
were excluded from the core set. 
      Agreement was also reached on the inclu-
sion criteria for patients and controls, a dedicated 
paper chart, a glossary for the study and statistical 
analysis. 
  There was no ﬁ  nancial support for the study. The 
ﬁ  nal study protocol was developed by the coordi-
nating centre. 
  Part  I 
  Seventeen experts from 12 centres, experienced 
in the diagnosis and care of CV, proposed a panel 
of 83 questions for patients with CV. Redundant 
questions were then deleted and among the 33 
remaining questions only those considered useful 
by at least two-thirds of the experts were selected: 
they included ﬁ  ve questions on purpura, four on 
peripheral nerve or muscular symptoms, two each 
on fatigue, articular involvement and oral or ocular 
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dryness, and one each on leg skin ulcers and   hepatitis virus 
infection (  table 1  ). 
    A questionnaire consisting of the 17 selected questions was 
then sent to each centre, where it was translated into the local 
language and administered to 20 consecutive unselected patients 
with CV (HCV-related or HCV-unrelated), and to 30 consecutive, 
unselected controls without CV in care in the same centre for at 
least 1 year. The controls, with or without serum cryoglobulins, 
included 10 patients with systemic vasculitis other than CV, four 
HCV antibody and HCV-RNA-positive patients without CV, 
four patients with primary Sjögren’s syndrome (SS), four with 
other connective tissue diseases, four with rheumatoid arthritis, 
polymyalgia rheumatica or seronegative spondyloarthritis, and 
four with any other condition where the differential diagnosis 
with CV was considered. The presence of cryoglobulins was 
assessed according to the local laboratory standard, based on 
reference methodologies,  15   and conﬁ  rmed by at least two posi-
tive tests at ≥12 weeks’ interval. 
   Part  II 
  The second and formal part of the study was a cooperative study 
involving 16 centres, some of which were different from those 
involved in study part I. A dedicated paper chart was developed 
and included the following core set of items for classiﬁ  cation: 
      a questionnaire for CV (with the questions selected in  1. 
study part I); 
      data (89 items) on the pattern of organ involvement  2. 
(present and past); 
      laboratory tests (28 items).  3. 
      The classiﬁ  cation of cases and controls as CV-positive and 
CV-negative was based on the ‘gold standard’ of an expert clini-
cian, who had never examined that case/control before. If CV had 
been diagnosed previously, the expert clinician had to redeter-
mine the diagnosis based on his/her gold standard judgement. 
  Patients and controls included additional, consecutive and 
unselected cases and controls not enrolled in part I of the study, 
subdivided as follows into three groups A, B and C: 
▶        Group A: patients with CV, (20 per centre) essential or 
associated with other disorders (HCV-related or HCV-
unrelated), with type I, II, III or non-typiﬁ  able circulat-
ing cryoglobulins  15   conﬁ  rmed by at least two positive 
tests at ≥12 weeks’ interval. 
▶        Group B: subjects (20 per centre) with serum cryo-
globulins, but lacking a CV based on the gold stan-
dard judgement of the expert clinician (20 controls per 
centre), to try to answer the question “if a patient has 
positive serum cryoglobulins, when should a CV be 
classiﬁ  ed?” For the inclusion of controls in this group, 
the minimum follow-up required was 1 year (ie, the 
expert did not notice any manifestations suggesting a 
CV, during all the available history of the patient, with 
a minimum of a 12-month history needed). 
▶        Group C: subjects without serum cryoglobulins (by at 
least two repeated tests during a follow-up of at least 
1 year), but with clinical or laboratory features which 
can be observed in the course of CV (40 controls per 
centre), to try to answer the question “if a patient has 
some features which pose a differential diagnosis from 
CV, even if negative for serum cryoglobulins by initial 
testing, when should a CV be suspected?”     
  Furthermore, a distinction in group C was made between 
patients with either systemic vasculitis (group C1: 20 controls 
per centre) or other diseases, which, however, should be distin-
guished from CV in clinical practice (group C2: 20 controls per 
 Table  1     Questions included in study part I: questions selected by monovariate and multivariate analysis     
 Questions   Sensitivity  (%)    95% CI (%)   Speciﬁ  city (%)    95% CI (%) 
Univariate analysis
    1. Do you remember one or more episodes of small red spots on your skin 
particularly involving the lower limbs?
81.9 76.3 to 87.4 68.3 62.8 to 73.7
    2. Had you ever had red spots in your lower extremities associated with 
itching or pain?
60.1 53.1 to 67.1 80.6 76.0 to 85.2
    3. Have you ever noticed small red dots on your legs and/or feet that don’t 
disappear when squeezed and take a long time to fade away?
67.0 60.3 to 73.8 83.4 79.1 to 87.8
    4. Had you ever had red spots in your lower extremities which leave a 
brownish colour after their disappearance?
69.2 62.5 to 75.8 85.2 81.1 to 89.3
    5. Do you remember episodes of small red spots or macules on your skin, 
particularly involving the lower limbs, arising in a few hours (eg, from one 
evening to the following morning) and usually lasting from a few days to 
1–2 weeks?
75.0 66.8 to 81.2 82.4 77.9 to 86.8
  10. Have you ever had bad or non-healing skin ulcers in your legs? 20.3 14.6 to 26.2 89.1 85.4 to 92.7
    12. Have you ever felt a burning sensation in your lower extremities for more 
than 1 month?
36.2 29.6 to 43.5 78.9 74.0 to 83.6
    13. Do you have a change of feeling (painful or changed sensation) and/or 
palsy of muscles in your extremities?
51.9 44.4 to 58.8 63.6 58.0 to 69.2
  14. Do you ever feel pins and needles in your legs or arms? 64.9 58.2 to 71.9 57.0 51.1 to 62.7
  17. Did a doctor ever tell you that you have viral hepatitis? 81.4 76.1 to 87.3 84.5 80.2 to 88.7
Multivariate analysis
  Question 1   ∪   Question 17 96.8 94.3 to 99.3 57.4 51.6 to 63.2
  Question 1   ∪   Question 4 83.5 78.2 to 88.8 67.6 61.2 to 73.1
  Question 4   ∪   Question 17 96.3 93.5 to 99.0 73.2 68.1 to 78.4
  Question 1   ∪   Question 4   ∪   Question 17 97.3 95.0 to 99.6 57.4 51.6 to 63.2
 Question  1  ∩ Question 17 66.5 59.7 to 73.3 95.4 93.0 to 97.9
 Question  1  ∩ Question 4 67.6 60.8 to 74.3 85.9 81.8 to 90.0
 Question  4  ∩ Question 17 54.3 47.1 to 61.4 96.5 94.3 to 98.6
 Question  1  ∩ Question 4 ∩ Question 17 53.2 46.0 to 60.4 97.2 95.2 to 99.1
  Positive response for at least any two out of the three questions 1, 4, 17 81.9 76.4 to 87.4 83.5 79.1 to 87.8
   ∪  ,  union;  ∩,  intersection.   
03_annrheumdis150755.indd   1184 03_annrheumdis150755.indd   1184 5/26/2011   5:12:28 PM 5/26/2011   5:12:28 PMCriteria
Ann Rheum Dis 2011;70:1183–1190. doi:10.1136/ard.2011.150755 1185
centre). Patients in group C had a previous follow-up of at least 
12 months to allow a deﬁ  nite diagnosis, other than CV. 
  The classiﬁ   cation criteria for CV developed by comparing 
data in group A (CV) versus group B (positive serum cryoglobu-
lins without CV) were then also tested by comparing group A 
versus group C (as a whole, or distinguishing C1 and C2). 
  All the patients and controls underwent a complete   physical 
examination. The response to the selected questions, the clini-
cal and laboratory core set data, plus instrumental tests and 
possibly additional investigations required by the clinician, 
were recorded in the chart. Chest x-ray and abdomen ultra-
sound examinations had to be performed in the 6 months 
before or at the time of the gold standard evaluation. If respira-
tory symptoms or abnormal thorax x-ray ﬁ  ndings were pres-
ent, a pulmonary function test, CO diffusion test and/or chest 
CT scanning had to be performed whenever possible, and 
electromyography was recommended if peripheral neuropathy 
was suspected. 
  All the data were entered and analysed by the coordinating centre 
of the study—namely, Rheumatology Clinic, Azienda Ospedaliero-
Universitaria ‘S Maria della Misericordia’, Udine, Italy.     
  DATA  ANALYSIS  METHODS 
  Sample  size 
  Sample size estimation was derived from the accuracy of the 
estimation of the 95% CI (two-sided) for each sensitivity and 
speciﬁ  city value.   
    Part I of the study 
  A sample size of 216 cases was necessary for a sensitivity of 
90% with a precision of ±4% at a two-sided conﬁ  dence level of 
95%. With the same precision of ±4% at a two-sided conﬁ  dence 
level of 95%, the sample size required to estimate a speciﬁ  city 
of 85%, was 306 controls. A higher sensitivity of the question-
naire was then presumed a priori. 
  A univariate analysis was carried out using χ  2   test to identify 
the questions associated with CV. A stepwise multiple logistic 
regression was used to select the questions with greater accu-
racy to correctly classify patients and controls and then to select 
the best combination for classiﬁ  cation. When different ‘additive 
or multiplicative’ combinations of questions were tested, the 
rule for classiﬁ  cation was that ‘for a given subject, at least   s   of 
the   n   questions were present’. If so, the subject was classiﬁ  ed as 
having CV.   
    Part II of the study 
  Since classiﬁ   cation criteria aim to have a high speciﬁ  city, 
together with a reasonable sensitivity, a sample size of 216 con-
trols was calculated, estimating a speciﬁ  city of 90% with a pre-
cision of ±4% at a two-sided conﬁ  dence level of 95%, while 
the sample size to estimate a sensitivity of 85% with the same 
precision of ±4% was 306 cases. 
  A univariate analysis was carried out to identify the questions, 
the clinical features and laboratory tests associated with CV. The 
items signiﬁ  cantly associated with CV by univariate analysis 
were then analysed by a stepwise multiple logistic regression. 
This analysis was performed separately for questions, clinical 
features and laboratory tests. 
  Then, different ‘additive or multiplicative’ combinations of 
items were tested for sensitivity and speciﬁ  city. The rule was 
that ‘for a given subject, at least   s   of the   n   items were present’. 
  Finally, with the same analysis, the best combination of the 
three sets of items—that is, the set of questions, the set of 
clinical features and the set of laboratory tests, was analysed to 
determine the ﬁ  nal classiﬁ  cation criteria. 
  A tree-based model was also used as an alternative method 
to correctly classify patients and controls.  6     7     13   The model is ﬁ  t-
ted by binary recursive partitioning whereby a dataset is suc-
cessively split into increasingly homogeneous subsets until it is 
infeasible to continue.     
  RESULTS 
    Part I of the study 
  Of the 12 selected centres, 10 completed this part of the study, 
for a total of 484 questionnaires available. The results of the 
questionnaires were received in electronic form by the coordi-
nating centre and were rechecked with the corresponding paper 
charts. Of the 484 questionnaires, 472 were used for statistical 
analysis (the remaining 12 were incomplete). 
  Cases comprised 188 subjects (68.1% women), with a mean 
age of 59.18±15.14 years; controls were 284 subjects (72.5% 
women), with a mean age of 53.76±15.24 years. 
  Univariate analysis identiﬁ  ed questions 1, 2, 3, 4, 5, 10, 12, 
13, 14 and 17 as associated with CV, but the logistic model 
showed that only questions 1, 4 and 17 contributed signiﬁ  -
cantly to the predictability of the disease. The sensitivity and 
speciﬁ  city of each question, and of all the possible combina-
tions of positive answers to questions 1, 4 and 17, are shown 
in   table 1  . 
  The best rule for classiﬁ  cation was a positive response to at 
least two of the three questions 1, 4 and 17, with a sensitivity 
of 81.9% (estimated with a precision of 5.5%) and a speciﬁ  city 
of 83.5% (with a precision of 4.4%) for CV. In addition to ques-
tions 1, 4 and 17, questions 10, 12 and 14 were also included in 
part II of the study, since the experts considered that repeated 
investigation was worthwhile for skin ulcers and peripheral 
neuropathy, based on the results of univariate analysis.   
    Part II of the study 
  Overall, 925 charts were received by the coordinating centre, 
which performed the electronic data entry, checked three times 
before data analysis. 
  Group A included 272 patients with CV (73.5% women), with 
a mean age 62.8±11.8 years. Group B included 228 controls with 
serum cryoglobulins but lacking a CV (68.4% women), mean 
age 58.4±15.4 years. Group C included 425 controls lacking 
serum cryoglobulins though with clinical or laboratory features 
which can be observed in the course of CV (72.2% women), 
mean age 56.0±16.8 years, divided into 173 controls in group 
C1 (systemic vasculitis other than CV: 63.6% women, mean age 
58.3±17.8 years) and 252 controls in group C2 (other diseases: 
78.2% women, mean age 54.5±16.0 years). Cases in group C1 
comprised 55 antineutrophil cytoplasmic antibody-associated 
vasculitis (Wegener’s granulomatosis, Churg–Strauss syndrome, 
micropolyarteritis), 47 giant cell arteritis, 15 isolated cutane-
ous vasculitis, 14 Schönlein–Henoch purpura, 12 panarteritis 
nodosa, 9 Takayasu arteritis, 6 Beçhet disease, 2 Goodpasture’s 
syndrome, 13 other vasculitis. Cases in group C2 were 52 SS, 
36 systemic sclerosis, 35 systemic lupus erythematosus, 
30 rheumatoid arthritis, 11 polymyositis or dermatomyositis, 
10 spondyloarthritis, 7 polymyalgia rheumatica, 3 antiphos-
pholipid syndrome, 3 undifferentiated connective tissue disease 
and 1 mixed connective tissue disease, and 64 with other dis-
eases which should be distinguished from CV in clinical prac-
tice (including 31 chronic HCV infection, 20 haematological 
malignancies and various other conditions such as sarcoidosis, 
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erythema nodosum, idiopathic thrombocytopenic purpura, pal-
indromic rheumatism, venous insufﬁ  ciency in lower limbs). The 
group distribution is reported in   table 2  .     
  Overall, about 89  000 clinical items and 18  000 laboratory 
items were ﬁ  led.   
    Comparison of group A with group B (cryoglobulinaemic 
syndrome versus serum cryoglobulinaemia without syndrome) 
and development of the classiﬁ  cation criteria 
  Questionnaire  validation 
  All the six questions included in part II of the study were sig-
niﬁ  cantly associated with CV by the univariate analysis, but 
only questions 1, 4 and 17 (  table 3  ) were also selected by the 
multivariate analysis. This fully replicated the results of part I 
of the study, even if the controls were selected differently in 
part II.   
  When different ‘additive or multiplicative’ combinations were 
tested on the three questions, the best criterion was ‘at least two 
out of the three questions’, giving a sensitivity of 83.8%, 95% 
CI (79.4% to 88.2%) and a speciﬁ  city of 93.8%, 95% CI (90.7% 
to 97.0%) for CV. The sensitivity and speciﬁ  city of this combi-
nation were higher in study part II than in study part I (81.9% 
and 83.5%, respectively). Thus, these results of part II of the 
study validated a three-question-based questionnaire for CV 
developed by study part I.   
  Clinical  features 
  Constitutional symptoms fatigue, low-grade fever (37–37.9°C 
for more than 10 days) or fever (≥38°C), or ﬁ  bromyalgia,  16   artic-
ular involvement (arthralgias or arthritis), vascular involvement 
(purpura, skin ulcers, necrotic skin lesions or necrotising vascu-
litis biopsy-proven, Raynaud’s phenomenon, or hyperviscosity 
syndrome according to clinical features and plasma viscosity 
test) and neurological involvement (peripheral neuropathy 
conﬁ  rmed by electromyography or conﬁ  rmed by a neurolo-
gist in electromyography-negative cases, cranial nerve involve-
ment conﬁ  rmed by a neurologist, or central nervous system 
vasculitic involvement documented by imaging) were the clini-
cal items selected by the multivariate analysis, to establish CV 
in patients with positive serum cryoglobulins. Their sensitivity 
and speciﬁ  city values by the univariate analysis are shown in 
  table 3  . 
  The criterion of ‘at least three of the four items’ gave a sensi-
tivity of 70.2%, 95% CI (64.7% to 75.8%) and a speciﬁ  city of 
84.5%, 95% CI (79.5% to 89.4%) for CV, while the criterion of 
‘at least two of the four items’ gave a higher sensitivity (90.1%, 
95% CI 86.4% to 93.7%) but a much lower speciﬁ  city (65.5%, 
95% CI 59.0% to 72.1%) for CV.   
  Laboratory  features 
  Reduced C4 levels, positive RF and the presence of serum M 
component (present in type I or II cryoglobulins, or detected 
by serum protein electrophoresis and immunoﬁ  xation)  were 
the laboratory items selected by the multivariate analysis, to 
establish a CV in patients with positive serum cryoglobulins. 
Sensitivity and speciﬁ  city in the univariate analysis are shown 
in   table 3  . The criterion of ‘at least two out of the three features’ 
gave a sensitivity of 84.2%, 95% CI (79.4% to 89.0%) and a 
speciﬁ  city of 79.6%, 95% CI (73.4% to 85.9%) for CV.   
    Classiﬁ  cation criteria for the cryoglobulinaemic syndrome 
  By analysing the best combination of the three sets of items—
that is, the set of questions (≥2 of 3), the set of clinical features 
(≥3 of 4), and the set of laboratory tests (≥2 of 3), to determine 
the ﬁ  nal classiﬁ  cation criteria, the criterion of at least two out of 
three questionnaire, clinical and laboratory sets of items (ques-
tionnaire + clinical; questionnaire + laboratory; or clinical + 
laboratory) provided a sensitivity of 88.5%, 95% CI (84.3% to 
92.8%) with a precision of ±4.3%, and a speciﬁ  city of 93.6%, 
95% CI (89.5% to 97.7%) with a precision of ±4.1% for CV 
(  table 4   and   ﬁ  gure 1  ).       
Other combinations, including the validated questions plus 
the positivity of lower or higher numbers of clinical or labora-
tory items, provided worse results, and the cost of a higher sen-
sitivity was a low speciﬁ  city for classiﬁ  cation purposes. 
  A tree-based model for predicting CV, derived by applying the 
criterion of ‘at least two out of’ the three questionnaire (1), clini-
cal (2) and laboratory (3) features, to 272 patients with CV and 
228 controls with serum cryoglobulins but lacking a CV is shown 
in   ﬁ  gure 2  . The probability of CV for patients with positive 
 Table  2     Composition of groups of patients in study part II   
   Group  A   Group  B   Group  C   Group  C1   Group  C2 
No of patients 272 228 425 173 252
Mean age (SD) 62.8 (11.8) 58.4 (15.4) 56.0 (16.8) 58.3 (17.8) 54.5 (16.0)
Sex (M/F) 72/200 72/156 118/307 63/110 55/197
Cryo type I (%) 5 (1.8) 1 (0.4) – – –
Cryo type II (%) 194 (71.3) 40 (17.5) – – –
Cryo type III (%) 32 (11.8) 110 (48.2) – – –
Cryo not typiﬁ  able (%) 41 (15.1) 77 (33.8) – – –
Rheumatoid factor positivity (%) 85.8 46.3 25.2 12.4 33.9
Low C4 (%) 69.6 25.5 9.2 1.9 14.4
M component (%) 82.7 27.2 3.7 2.8 4.4
Truly essential cryo (%) 9 (3.3) 7 (3.1) – – –
HCV infection (%)  *  230 (84.6) 153 (67.1) 31 (7.3) – 31 (12.3)
SS (%) 39 (14.4) 34 (14.9) 52 (12.2) – 52 (20.6)
Other CTDs  †   (%) 5 (1.8) 30 (13.2) 89 (20.9) – 89 (35.3)
Other vasculitis  ‡   (%) – – 173 (40.7) 173 (100) –
Other diseases  ‡ (%) 10 (3.7) 8 (3.5) 80 (18.8) – 80 (31.7)
      *    HCV infection could be also concomitant with SS or with other connective tissue diseases.   
  †    Systemic lupus erythematosus, systemic sclerosis, poly/dermatomyositis, undifferentiated connective tissue disease, mixed 
connective tissue disease, antiphospholipid syndrome.   
  ‡    In groups A and B, positivity for the hepatitis B virus surface antigen was noticed in 10 and in eight cases, respectively; see text for 
other diseases included in group C, to be differentiated from CV.   
    CTDs, connective tissue diseases; CV, cryoglobulinaemic vasculitis; F, female; HCV, hepatitis C virus; M, male; SS, Sjögren’s 
syndrome.   
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questionnaire and laboratory criteria was 99.4%. The ﬁ  nal prob-
ability of CV provided by the tree-based model (‘at least two out 
of the three questions’ → ‘at least two out of the three labora-
tory features’ → ‘at least three out of the four clinical features’) 
was 100%. Similarly, the probability of lacking CV for patients 
who did not satisfy the questionnaire and laboratory criteria was 
92.1%, and the ﬁ  nal probability of lacking CV provided by the 
tree-based model (‘less than two out of the three questions’ → 
‘less than two out of the three laboratory features’ → ‘less than 
three out of the four clinical features’) was 94.6% (  ﬁ  gure 2  ).       
    Comparison of group A with group C (cryoglobulinaemic 
syndrome versus other diseases which may mimic 
the syndrome) 
  The classiﬁ   cation criteria developed in comparing group A 
with group B were applied for the comparison of group A with 
group C, to verify whether the classiﬁ  cation criteria may also 
be useful to suspect a CV in patients cryoglobulin-negative by 
initial testing, though showing clinical or laboratory features 
suggestive of CV. 
  The results of statistical analyses for questions, clinical mani-
festations and laboratory features associated with CV are shown 
in   table 4  . 
  The criteria provided satisfactory results for sensitivity 88.5%, 
95% CI (84.3% to 92.8%) and speciﬁ  city 97.0%, 95% CI (94.6% 
to 99.4%). 
  When further analysing group A versus group C1 (including 
only patients with systemic vasculitis other than CV), similar 
results were noticed (  table 4  ). 
  The ﬁ  nal criteria provided a sensitivity of 88.5%, 95% CI 
(84.3% to 92.8%) and a speciﬁ  city of 95.4%, 95% CI (90.9% to 
99.8%). Thus, if a systemic vasculitis is suspected, positive CV 
criteria, even in the absence of positive serum cryoglobulins by 
initial testing, should warn the clinician of a possible CV, and 
repeated cryoglobulin testing is mandatory.     
  DISCUSSION 
  The preliminary classiﬁ  cation criteria for the CV are presented—
the result of a multicentre European study. Classiﬁ  cation criteria 
for CV developed by a standardised methodology were lacking, 
though they are crucial in clinical practice, scientiﬁ  c communi-
cation and epidemiological surveys. A methodology similar to 
that employed for the classiﬁ  cation criteria for SS was used.  13     14   
This led, as a ﬁ  rst step, to the development of a dedicated ques-
tionnaire. The questionnaire was then validated and the set of 
classiﬁ  cation criteria for CV was deﬁ  ned, also including easily 
 Table  3     Results of group A vs group B analyses: sensitivity and speciﬁ  city of the different questions, clinical features and laboratory features 
included in the anamnestic, clinical and laboratory item, respectively   
   Sensitivity  (%)    95% CI (%)   Speciﬁ  city (%)    95% CI (%) 
Questionnaire  item     
   1  →1 Do you remember one or more episodes of small red spots on 
your skin particularly involving the lower limbs?
83.5 79.0 to 87.9 89.9 85.6 to 93.8
   4  → 2 Have you ever had red spots on your lower extremities which 
leave a brownish colour after their disappearance?
74.3 69.0 to 79.5 94.7 91.8 to 97.6
 17  → 3 Has a doctor ever told you that you have viral hepatitis? 83.1 78.6 to 87.6 38.6 32.2 to 44.9
Clinical item
  Constitutional symptoms 81.5 76.9 to 86.2 56.8 50.3 to 63.3
  Articular involvement 63.0 57.2 to 68.7 57.0 50.6 to 63.5
  Vascular involvement 87.9 84.0 to 91.8 78.5 73.1 to 83.9
  Neurological involvement 64.4 58.6 to 70.2 86.5 81.8 to 91.2
Laboratory item
  Low serum C4 69.6 64.0 to 75.2 74.5 68.3 to 80.6
  Rheumatoid factor (RF) positivity 85.8 81.5 to 90.1 53.7 46.8 to 60.7
  Presence of serum M component 83.1 78.4 to 87.8 72.8 66.2 to 79.3
Group A vs group B
  ’At least 2 out of the 3 questions’ 83.8 79.4 to 88.2 93.8 90.7 to 97.0
    ’At least 3 out of the 4 features’ among constitutional symptoms, 
articular, vascular or neurological involvement
70.2 64.7 to 75.8 84.5 79.5 to 89.4
    ’At least 2 out of the 3 features’ among serum C4 levels, RFs and 
serum M component
84.2 79.4 to 89.0 79.6 73.4 to 85.9
 Table  4     Results of group A vs group C, and of group A vs group C1 analyses: sensitivity and speciﬁ  city of the different questions, clinical features 
and laboratory features included in the anamnestic, clinical and laboratory item, respectively   
   Sensitivity  (%)    95% CI (%)   Speciﬁ  city (%)    95% CI (%) 
Group A vs group C
  ’At least 2 out of the 3 questions’ 83.8 79.4 to 88.2 90.6 87.8 to 93.4
    ’At least 3 out of the 4 features’ among constitutional symptoms, 
articular, vascular or neurological involvement
70.2 64.7 to 75.8 68.7 64.2 to 73.3
    ’At least 2 out of the 3 features’ among serum C4 levels, rheumatoid 
factors (RFs) and serum M component
84.2 79.4 to 89.0 97.7 95.7 to 99.7
Group A vs group C1 (systemic vasculitis)        
  ’At least 2 out of the 3 questions’ 83.8 79.4 to 88.2 85.5 80.3 to 90.8
    ’At least 3 out of the 4 features’ among constitutional symptoms, 
articular, vascular or neurological involvement
70.2 64.7 to 75.8 53.0 45.4 to 60.7
    ’At least 2 out of the 3 features’ among serum C4 levels, RFs and 
serum M component
84.2 79.4 to 89.0 100  
03_annrheumdis150755.indd   1187 03_annrheumdis150755.indd   1187 5/26/2011   5:12:29 PM 5/26/2011   5:12:29 PMCriteria
Ann Rheum Dis 2011;70:1183–1190. doi:10.1136/ard.2011.150755 1188
accessible clinical and laboratory items. The criteria showed 
a high speciﬁ  city and a good sensitivity for CV. In addition, 
although this was not the main purpose of the study, the same 
criteria were also investigated and proved useful in classifying 
CV in patients with negative serum cryoglobulins by initial 
  laboratory testing. 
  A uniform set of classiﬁ  cation criteria for CV was needed. 
Previous criteria were non-universal, employed by the experts 
who had proposed them, and lacked appropriate statistical 
support.  9    –    12   Guidelines for the management of CV have been 
recently proposed,  8   but uniform criteria to classify CV were not 
available at that time. 
  This study, proposed by GISC  9   included experts from ﬁ  ve 
European countries and with different backgrounds. The meth-
odology used, based on a gold standard preliminary diagnosis 
of CV, meets the current standards for classiﬁ  cation criteria in 
disorders characterised by the lack of a single, reliable diagnos-
tic test. For the ﬁ  nal set of classiﬁ  cation criteria, a combination 
showing a high speciﬁ  city was needed. This goal was achieved 
(speciﬁ  city of 93.6%), and a good sensitivity (88.5%) for CV 
was maintained, with a good precision for both. The questions 
selected in part I of the study proved relevant for classiﬁ  cation 
in study part II, by comparing patients with cryoglobulins and 
CV (group A) with patients with cryoglobulins but without CV 
(group B). 
  The results of this study conﬁ  rm that in CV, as in other auto-
immune diseases, classiﬁ   cation can be made by integrating 
different questionnaire, clinical and laboratory data. Of note, 
none of the three sets of items comprising the CV classiﬁ  cation 
criteria herein developed (positive answer to ≥2/3 validated 
questions, presence of ≥3/4 clinical features, or presence of 
≥2/3 laboratory abnormalities) is absolutely needed for classi-
ﬁ  cation itself, since classiﬁ  cation is possible with positivity for 
any two of the three questionnaire, clinical or laboratory items. 
This is an advantage for patients with CV with difﬁ  culties in 
completing a questionnaire, for patients with clinical features 
less common in CV (eg, abdominal vasculitis, serositis, glom-
erulonephritis, etc), or where laboratory data are uncertain for 
any reason. 
  Although this study shows that no ﬁ   xed combination of 
tests can be used to classify CV, the classiﬁ  cation tree suggests 
a sequence of tests to be followed in the diagnostic approach to 
the disease. A validated three-item questionnaire is useful for 
initial evaluation of the patient: if a patient has positive serum 
cryoglobulins and is also positive for the questionnaire criterion, 
the probability of CV is 94.4%, with a further increase to 99.4% 
if the laboratory criterion is also positive. This approach may be 
particularly useful if CV is highly suspected by doctors without 
extensive experience of this disease, before the evaluation of the 
specialist. Conversely, if a patient with serum cryoglobulins is 
negative for the questionnaire criterion and is also lacking the 
CV laboratory features included in the laboratory criterion, CV 
can be excluded with a probability of 92.1%. 
  One main criticism of these criteria is that they cannot be applied 
to patients with CV with negative serum cryoglobulins. This point 
was thoroughly discussed in study planning, where positive serum 
cryoglobulins were ﬁ  nally designated as an essential condition for 
CV classiﬁ  cation. For classiﬁ  cation purposes it was established 
that it is not possible to classify the CV if the characterising fea-
ture—that is, positive serum cryoglobulins, is not demonstrated. 
However, it was agreed that if cryoglobulinaemia is absent at a 
deﬁ  nite evaluation point, but has been well documented in the 
past (eg, before antiviral or anti-CD20 treatment), cryoglobulin 
positivity rather than negativity must be considered. 
  There is a subset of CV in which serum cryoglobulins may 
appear to be negative by initial laboratory testing for various 
reasons, such as low cryoglobulin levels, problems in blood 
sample handling or testing, or owing to tissue deposition rather 
than blood circulation of immune complexes. Such patients 
deserve a careful follow-up if CV is suspected, and must 
undergo repeat cryoglobulin determination, while excluding 
other diseases. This led to an extensive expert discussion on 
1
(i) Questionnaire item:  at least two out of the following 
￿ Do you remember one or more episodes of small red spots on your skin, particularly involving the lower 
limbs?
￿ Have you ever had red spots on your lower extremities which leave a brownish color after their 
disappearance?
￿ Has a doctor ever told you that you have viral hepatitis?
Clinical item : at least three out of the following four (present or past)*
￿ Constitutional symptoms Fatigue
Low grade fever (37–37.9°C, >10 days, no cause)
Fever (>38°C, no cause)
Fibromyalgia
￿ Articular involvement Arthralgias
Arthritis




Raynaud Raynaud’ ’ phenomenon phenomenon
￿ Neurologic Neurologic involvement involvement Peripheral Peripheral neuropathy neuropathy
Cranial Cranial nerve  nerve involvement involvement
Vasculitic CNS involvement Vasculitic CNS involvement
iii. Laboratory item : at least two out of the following three (present)
￿ Reduced serum C4
￿ Positive serum rheumatoid factor
￿ Positive serum M component
Questionnaire item:  at least two out of the following 
￿ Do you remember one or more episodes of small red spots on your skin, particularly involving the lower 
limbs?
￿ Have you ever had red spots on your lower extremities which leave a brownish color after their 
disappearance?
￿ Has a doctor ever told you that you have viral hepatitis?
(ii) Clinical item : at least three out of the following four (present or past)*
￿
(37–37.9°C, >10 days, no cause)









iii. Laboratory item : at least two out of the following three (present)
￿ Reduced serum C4
￿ Positive serum rheumatoid factor
￿ Positive serum M component
Satisfied  if at least two of the three items (questionnaire, clinical, laboratory ) are positive
the patient must be positive for serum cryos in at least 2 determinations at ≥ 12 week interval
*See text for details
s 
 Figure  1        Preliminary classiﬁ  cation criteria for the cryoglobulinaemic vasculitis.       
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classiﬁ  cation problems in these cases, and the study was ﬁ  nally 
designed in an attempt to clarify whether classiﬁ  cation criteria 
(developed by comparing cryoglobulin-positive patients with 
or without CV) might be of some relevance for CV diagnosis 
when serum cryoglobulins appear to be absent. By compar-
ing data in group A with those in group C, it was shown that 
the classiﬁ  cation criteria were useful in such cases, since posi-
tive criteria were rarely present in diseases that may mimic 
CV, including a group of patients (C1) with systemic vasculitis 
other than CV. Then, if CV is suspected, positive classiﬁ  cation 
criteria for CV in that patient, even in the absence of detect-
able cryoglobulins by initial testing, warn the clinician to repeat 
the cryoglobulin determination, and classiﬁ  cation of CV may 
be possible in the follow-up. This part of the study supported 
the clinical practice of repeating cryoglobulin laboratory deter-
mination if CV is highly suspected on clinical grounds, and the 
relevance of sample handling and high-quality laboratory refer-
ral for CV assessment. 
  Second, an extremely small number of patients with CV and 
type I cryoglobulins were included in this study, and this in 
part reﬂ  ects the rarity of this subset, which usually occurs in 
the course of an overt B-cell lymphoproliferative disorder. All 
except one of these cases were correctly classiﬁ  ed with the crite-
ria developed (data not shown). However, these criteria cannot 
be formally proposed for patients with type I cryoglobulinae-
mia, and the experts agreed that this patient subset should be 
expanded in subsequent validation studies. 
  Furthermore, the distinction between classiﬁ  cation and diag-
nostic criteria should be emphasised. Classiﬁ  cation criteria are 
constructed mainly for investigation and epidemiological pur-
poses, and aim at a higher speciﬁ  city.  6     7   By contrast, the diag-
nosis of a disease can be formulated by the expert clinician also 
in patients lacking the classiﬁ  cation criteria for that disease, and 
prompt diagnosis and treatment decisions are certainly more rel-
evant in clinical practice.  13     17    –    19   We would at present discourage 
the use of these classiﬁ  cation criteria for diagnostic purposes, 
and additional data analyses are under way. 
  In conclusion, preliminary classiﬁ  cation criteria for CV have 
been developed by a cooperative study using a standardised 
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 Figure  2     Schematic representation of the classiﬁ  cation tree for the cryoglobulinaemic vasculitis (CV). Within each circle and box is the number 
of the patients with CV according to the ‘gold standard’ (upper value) and the number of controls without CV according to the gold standard (lower 
value). Interior nodes are denoted by circles and terminal nodes by boxes. The criterion used in each node of the tree to discriminate between cases 
and controls is reported beneath the circles. Details of the three-item criterion set, questionnaire, clinical and laboratory, are given in Figure 1; they 
were assessed by the binary recursive partitioning method. Only those subjects for whom the entire three-item criterion set was available were 
included in this procedure (358 subjects: 218 patients with CV and 140 controls). The sequential approach selected the questionnaire item as the ﬁ  rst 
node of the tree, which divided the 358 observations into groups of 160 and 198 individuals, with a probability of CV of 19.4% (less than two out of the 
three questions) and 94.4% (at least two out of the three questions), respectively. The latter group, with greater probability of CV, was then partitioned 
into groups of 35 and 163 individuals, depending on whether the item ‘at least two out of the three laboratory features’ was satisﬁ  ed. The respective 
probabilities of CV for these groups were 71.4% and 99.4%, respectively.   Both these groups were further subdivided by the item ‘at least three out 
of the four clinical features’, and the latter one, with greater probability of CV (99.4%) was partitioned into groups of 36 and 127 individuals with 
probability of CV of 97.2% and 100%, respectively. Then, the ﬁ  nal probability of CV provided by the tree-based model (‘at least two out of the three 
questions’ → ‘at least two out of the three laboratory features’ → ‘at least three out of the four clinical features’) was 100%, based on 127 individuals. 
Similarly, the ﬁ  nal probability of lacking a CV, beginning from the ﬁ  rst node of the tree, was 80.6% (less than two out of the three questions) and 5.6% 
(at least two out of the three questions), respectively. The former group, with greater probability of lacking a CV, was then partitioned into groups of 
114 and 46 individuals depending on whether the item ‘at least two out of the three laboratory features’ was or was not satisﬁ  ed. The probabilities 
of lacking a CV for these groups were 92.1% (less than two out of the three laboratory features) and 52.2% (at least two out of the three laboratory 
features). Both these groups were further subdivided by the item ‘at least three out of the four clinical features’, and the former one, with greater 
probability of lacking a CV (92.1%) was partitioned into groups of 92 (less than three out of the four clinical features) and 22 (at least three out of the 
four clinical features) individuals with probability of lacking a CV of 94.6% and 81.8%, respectively. Then, the ﬁ  nal probability of lacking CV provided 
by the tree-based model (‘less than two out of the three questions’ → ‘less than two out of the three laboratory features’ → ‘less than three out of the 
four clinical features’) was 94.6%, based on 92 individuals.       
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formal validation, possibly involving experts from a larger num-
ber of countries.  20     21   In addition, they should be further tested 
in HCV-related versus HCV-unrelated CV. These studies, as well 
as more descriptive analyses and subanalyses, are continuing or 
have been planned. 
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